We maintain a BUY rating on the stock and revise our TP upwards at Rs 630 (SOTP based) from Rs 570, implying an upside of 15% from the CMP. We use a 12MF EV/EBITDA multiple of 5.5x for Indian business and 6.5x for the Novelis operations on FY24 EBITDA estimates.